Literature DB >> 24089019

A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.

Huiling Yuan1, Fujun Qin, Mercedeh Movassagh, Hong Park, Wendy Golden, Zhongqiu Xie, Peng Zhang, Jeffrey Sklar, Hui Li.   

Abstract

UNLABELLED: Gene fusions and their chimeric products are common features of neoplasia. Given that many cancers arise by the dysregulated recapitulation of processes in normal development, we hypothesized that comparable chimeric gene products may exist in normal cells. Here, we show that a chimeric RNA, PAX3-FOXO1, identical to that found in alveolar rhabdomyosarcoma, is transiently present in cells undergoing differentiation from pluripotent cells into skeletal muscle. Unlike cells of rhabdomyosarcoma, these cells do not seem to harbor the t(2;13) chromosomal translocation. Importantly, both PAX3-FOXO1 RNA and protein could be detected in the samples of normal fetal muscle. Overexpression of the chimera led to continuous expression of MYOD and MYOG-two myogenic markers that are overexpressed in rhabdomyosarcoma cells. Our results are consistent with a developmental role of a specific chimeric RNA generated in normal cells without the corresponding chromosomal rearrangement at the DNA level seen in neoplastic cells presumably of the same lineage. SIGNIFICANCE: A chimeric fusion RNA, PAX3-FOXO1, associated with alveolar rhabdomyosarcoma, is also present in normal non-cancer cells and tissues. Its transient expression nature and the absence of t(2;13) chromosomal translocation are consistent with a posttranscriptional mechanism. When constantly expressed, PAX3-FOXO1 interfered with the muscle differentiation process, which presumably contributes to tumorigenesis. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089019     DOI: 10.1158/2159-8290.CD-13-0186

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  40 in total

1.  Investigation of fusion gene expression in HCT116 cells.

Authors:  Yanmei Zhang; Juan Ren; Mengdie Fang; Xiaoju Wang
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

2.  Fusion RNA profiling provides hints on cell of origin of mysterious tumor.

Authors:  Zhongqiu Xie; Hui Li
Journal:  Mol Cell Oncol       Date:  2016-11-29

Review 3.  Trans-spliced long non-coding RNA: an emerging regulator of pluripotency.

Authors:  Chun-Ying Yu; Ching-Yu Chuang; Hung-Chih Kuo
Journal:  Cell Mol Life Sci       Date:  2018-06-30       Impact factor: 9.261

4.  Functional heritage: the evolution of chimeric RNA into a gene.

Authors:  Hao Wu; Sandeep Singh; Xinrui Shi; Zhongqiu Xie; Emily Lin; Xiaorong Li; Hui Li
Journal:  RNA Biol       Date:  2019-09-29       Impact factor: 4.652

5.  Recurrent cis-SAGe chimeric RNA, D2HGDH-GAL3ST2, in prostate cancer.

Authors:  Fujun Qin; Zhenguo Song; Maxwell Chang; Yansu Song; Henry Frierson; Hui Li
Journal:  Cancer Lett       Date:  2016-06-17       Impact factor: 8.679

Review 6.  Identifying fusion transcripts using next generation sequencing.

Authors:  Shailesh Kumar; Sundus Khalid Razzaq; Angie Duy Vo; Mamta Gautam; Hui Li
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-08-02       Impact factor: 9.957

Review 7.  Intergenically Spliced Chimeric RNAs in Cancer.

Authors:  Yuemeng Jia; Zhongqiu Xie; Hui Li
Journal:  Trends Cancer       Date:  2016-09

8.  Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma.

Authors:  Zhongqiu Xie; Mihaela Babiceanu; Shailesh Kumar; Yuemeng Jia; Fujun Qin; Frederic G Barr; Hui Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 9.  Chimeric RNAs and their implications in cancer.

Authors:  Zi Li; Fujun Qin; Hui Li
Journal:  Curr Opin Genet Dev       Date:  2017-11-05       Impact factor: 5.578

10.  The discovery of AVIL as a bona fide oncogene in glioblastoma.

Authors:  Zhongqiu Xie; Hui Li
Journal:  Mol Cell Oncol       Date:  2020-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.